Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: mavacamten

Obstructive hypertrophic cardiomyopathy

REMS Update: Mavacamten Still Effective in Treating Real-World Patients With HCM

Few patients report left ventricular dysfunction or heart failure after one year

cardiac MRI showing obstructive hypertrophic cardiomyopathy

Final VALOR-HCM Report: At 128 Weeks, Mavacamten Sustains Gains in HCM Patients

Avoidance of septal reduction therapy continues while LVEF dysfunction remains infrequent

echocardiogram showing strain imaging assessment

Mavacamten’s Effects on Strain Imaging in Obstructive HCM: Insights From VALOR-HCM

Serial strain assessments show sustained favorable impacts on LV systolic function and LA function

heart showing obstructive cardiomyopathy

Mavacamten in the Real World: Study Demonstrates Safe Reduction in Eligibility for Septal Reduction Therapy

Logistic feasibility supported for treating obstructive HCM under the REMS program

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

23-HVI-4172009 CQD 650×450-2

Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

22-HVI-3509429_obstructive-hypertrophic-cardiomyopathy_650x450

Advances in Hypertrophic Cardiomyopathy Therapy: VALOR-HCM May Be Just the Beginning

An abundance of promising studies are on the horizon

22-HVI-3393756_echo-showing-obstructive-HCM_ 650×450

VALOR-HCM Substudy: Mavacamten Improves Left Ventricular Diastolic Function

Gains are associated with clinical and biomarker benefits in obstructive HCM

22-HVI-3276959_obstructive-HCM-strain-imaging_650x450

Mavacamten’s Effects Against Obstructive Hypertrophic Cardiomyopathy Persist Through 32 Weeks in VALOR-HCM

Latest results confirm and build on 16-week findings

22-HVI-2769712_hyptertrophic-cardiomyopathy_650x450

Mavacamten Significantly Reduces Patients’ Need for Septal Reduction Therapy Over 16 Weeks

Longer-term confirmation of VALOR-HCM could yield a noninvasive therapy for severe obstructive HCM

cardiac magnetic resonance images showing hypertrophic cardiomyopathy

Hypertrophic Cardiomyopathy: Signs of Progress Toward a Medical Therapy and Refined Risk Prediction

New and ongoing studies aim to reduce the need for surgery, improve risk stratification

BackPage 1 of 1Next

Advertisement

Ad